1,360$
3,82%
Echtzeit-Aktienkurs Aclaris Therapeutics Inc.
Bid:
Ask:
Echtzeit-Chart der Aclaris Therapeutics Inc. Aktie
Börsenkurse Aclaris Therapeutics Inc.
| gettex | - | - | - | - | 1,211€ | 3,33% |
| Tradegate | - | - | - | - | 1,211€ | 9,67% |
| Nasdaq | - | - | - | - | 1,360$ | 3,82% |
| Börse Stuttgart | - | - | - | - | 1,211€ | 4,22% |
| Echtzeit USD | - | - | - | - | 1,363$ | 4,07% |
| Echtzeit Euro | - | - | - | - | 1,211€ | 9,92% |
| USA | - | - | - | - | 1,310$ | 4,80% |
| Lang & Schwarz | - | - | - | - | 1,211€ | 3,37% |
Fundamentaldaten der Aclaris Therapeutics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 18,72 Mio. | -132,07 Mio. | -132,07 Mio. | -1,71 | - | - | 7,87 |
| 2023 [USD] | 31,25 Mio. | -88,85 Mio. | -88,48 Mio. | -1,27 | - | - | 3,09 |
| 2022 [USD] | 29,75 Mio. | -86,91 Mio. | -86,91 Mio. | -1,33 | - | - | 3,05 |
| 2021 [USD] | 6,76 Mio. | -90,87 Mio. | -90,87 Mio. | -1,60 | - | - | 12,32 |
| 2020 [USD] | 6,48 Mio. | -51,34 Mio. | -51,02 Mio. | -1,20 | - | - | 9,46 |
| 2019 [USD] | 4,23 Mio. | -113,54 Mio. | -161,35 Mio. | -3,91 | - | - | 13,35 |
| 2018 [USD] | 10,09 Mio. | -132,74 Mio. | -132,74 Mio. | -4,03 | - | - | 5,55 |
| 2017 [USD] | 1,68 Mio. | -70,35 Mio. | -68,52 Mio. | -2,44 | - | - | 24,93 |
| 2016 [USD] | - | -48,08 Mio. | -48,08 Mio. | -2,25 | - | - | - |
| 2015 [USD] | - | -20,56 Mio. | -20,56 Mio. | -3,79 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Aclaris Therapeutics Inc. Aktie
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.